Table 1.
The association of antimicrobial susceptibilities with CRISPR-Cas systems in clinical isolates of Klebsiella pneumoniae.
| CRISPR-Cas system [Number of susceptible isolates (%)] | |||||
|---|---|---|---|---|---|
| Type I-E* (n = 111) | Type I-E (n = 54) | Absent (n = 533) | p-value | ||
| Amikacin | 98 (88.3) | 49 (90.7) | 346 (64.9) | <0.001 | <0.001 |
| Aztreonam | 72 (64.9) | 39 (72.2) | 208 (39.0) | <0.001 | <0.001 |
| Cefotaxime | 65 (58.6) | 35 (64.8) | 171 (32.1) | <0.001 | <0.001 |
| Cefoxitin | 83 (74.8) | 35 (64.8) | 232 (43.5) | <0.001 | <0.001 |
| Ceftazidime | 74 (66.7) | 38 (70.4) | 214 (40.2) | <0.001 | <0.001 |
| Ceftazidime-avibactam | 110 (99.1) | 53 (98.1) | 508 (95.3) | 0.067 | 0.499 |
| Chloramphenicol | 71 (64.0) | 29 (53.7) | 218 (40.9) | <0.001 | 0.082 |
| Ciprofloxacin | 66 (59.5) | 28 (51.9) | 158 (29.6) | <0.001 | 0.001 |
| Colistin | 109 (98.2) | 54 (100.0) | 506 (94.9) | 0.205 | 0.161 |
| Ertapenem | 96 (86.5) | 47 (87.0) | 278 (52.2) | <0.001 | <0.001 |
| Fosfomycin | 80 (72.1) | 34 (63.0) | 248 (46.5) | <0.001 | 0.021 |
| Imipenem | 100 (90.1) | 48 (88.9) | 296 (55.5) | <0.001 | <0.001 |
| Meropenem | 98 (88.3) | 50 (92.6) | 305 (57.2) | <0.001 | <0.001 |
| Minocycline | 35 (31.5) | 16 (29.6) | 152 (28.5) | 0.525 | 0.863 |
| Tigecycline | 95 (85.6) | 45 (83.3) | 432 (81.1) | 0.282 | 0.855 |
| Trimethoprim-sulfamethoxazole | 49 (44.1) | 17 (31.5) | 147 (27.6) | 0.001 | 0.543 |
p-values are shown as CRISPR-negative isolates compared with type I-E* isolates and CRISPR-negative isolates compared with type I-E isolates. The bold p-values were statistically significant.